Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Low molecular weight heparin for prevention of thromboembolic complications in cardioversion--rationale and design of the ACE study (Anticoagulation in Cardioversion using Enoxaparin).

Stellbrink C, Hanrath P, Nixdorff U, Hofmann T, Lehmacher W, Kühle K, Fetsch T, Grewe R, Schmidt-Lucke JA; Anticoagulation in Cardioversion using Enoxaparin Study Group..

Z Kardiol. 2002 Mar;91(3):249-54.

PMID:
12001541
2.

Use of subcutaneous enoxaparin compared to intravenous heparin and oral phenprocoumon in the setting of cardioversion--the ACE study (Anticoagulation in Cardioversion using Enoxaparin).

Stellbrink C, Nixdorff U, Hofmann T, Lehmacher W, Daniel WG, Hanrath P, Geller C, Mügge A, Sehnert W, Schmidt-Lucke C, Schmidt-Lucke JA; Anticoagulation in Cardioversion using Enoxaparin Study Group..

Card Electrophysiol Rev. 2003 Dec;7(4):382-6.

PMID:
15071260
3.

Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.

Stellbrink C, Nixdorff U, Hofmann T, Lehmacher W, Daniel WG, Hanrath P, Geller C, Mügge A, Sehnert W, Schmidt-Lucke C, Schmidt-Lucke JA; ACE (Anticoagulation in Cardioversion using Enoxaparin) Study Group..

Circulation. 2004 Mar 2;109(8):997-1003. Epub 2004 Feb 16.

4.

Economic evaluation of enoxaparin for anticoagulation in early cardioversion of persisting nonvalvular atrial fibrillation: a statutory health insurance perspective from Germany.

Schädlich PK, Schmidt-Lucke C, Huppertz E, Lehmacher W, Nixdorff U, Stellbrink C, Brecht JG.

Am J Cardiovasc Drugs. 2007;7(3):199-217.

PMID:
17610347
5.

Post-cardioversion transesophageal echocardiography (POSTEC) strategy with the use of enoxaparin for brief anticoagulation in atrial fibrillation patients: the multicenter POSTEC trial (a pilot study).

Sorino M, Colonna P, De Luca L, Carerj S, Oliva E, De Tommasi SM, Conti U, Iacopi F, D'Agostino C, D'Amato N, Pettinati G, Montericcio V, Cualbu A, De Luca I.

J Cardiovasc Med (Hagerstown). 2007 Dec;8(12):1034-42.

PMID:
18163016
6.

Quality of anticoagulation with unfractionated heparin plus phenprocoumon for the prevention of thromboembolic complications in cardioversion for non-valvular atrial fibrillation. Sub-analysis from the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.

Schmidt-Lucke C, Paar WD, Stellbrink C, Nixdorff U, Hofmann T, Meurer J, Grewe R, Daniel WG, Hanrath P, Mügge A, Klein HU, Schmidt-Lucke JA.

Thromb Res. 2007;119(1):27-34. Epub 2006 Jan 27.

PMID:
16443257
7.

Anticoagulation with the low-molecular-weight heparin dalteparin (Fragmin) in atrial fibrillation and TEE-guided cardioversion.

Bechtold H, Gunzenhauser D, Sawitzki H, Fung S, Janssen D.

Z Kardiol. 2003 Jul;92(7):532-9.

PMID:
12883837
8.
9.

Safety of expedited anticoagulation in patients undergoing transesophageal echocardiographic-guided cardioversion.

Wu LA, Chandrasekaran K, Friedman PA, Ammash NM, Ramakrishna G, Hart CY, Moon BS, Herges RM, Rosales AG, Malouf JF.

Am J Med. 2006 Feb;119(2):142-6.

PMID:
16443416
10.

Transesophageal echocardiography guided enoxaparin antithrombotic strategy for cardioversion of atrial fibrillation: the ACUTE II pilot study.

Murray RD, Shah A, Jasper SE, Goodman A, Deitcher SR, Katz WE, Malouf JF, Stoddard MF, Grimm RA, Klein AL; ACUTE II pilot study..

Am Heart J. 2000 Jun;139(6):E1-7.

PMID:
10827367
11.

A new therapeutic strategy for electrical cardioversion of atrial fibrillation.

de Luca I, Sorino M, Del Salvatore B, de Luca L.

Ital Heart J. 2001 Nov;2(11):831-40.

PMID:
11770868
12.

Health status outcomes after cardioversion for atrial fibrillation: results from the Assessment of Cardioversion Using Transesophageal Echocardiography (ACUTE) II Trial.

Elliott DJ, Zhao L, Jasper SE, Lieber EA, Klein AL, Weintraub WS.

Am Heart J. 2008 Aug;156(2):374.e1-6. doi: 10.1016/j.ahj.2008.05.008.

PMID:
18657673
13.

Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.

Merli G, Spiro TE, Olsson CG, Abildgaard U, Davidson BL, Eldor A, Elias D, Grigg A, Musset D, Rodgers GM, Trowbridge AA, Yusen RD, Zawilska K; Enoxaparin Clinical Trial Group..

Ann Intern Med. 2001 Feb 6;134(3):191-202.

PMID:
11177331
14.

AFFECT: a prospective, open-label, multicenter trial to evaluate the feasibility and safety of a short-term treatment with subcutaneous certoparin in patients with persistent non-valvular atrial fibrillation.

Tebbe U, Oeckinghaus R, Appel KF, Heuer H, Haake H, Eggers E, Seidel K, Adams J, Harenberg J.

Clin Res Cardiol. 2008 Jun;97(6):389-96. doi: 10.1007/s00392-008-0644-y. Epub 2008 Mar 5.

PMID:
18322636
15.

[Anticoagulation in cardioversion of atrial fibrillation. Current status and outlook for the future].

Schimpf T, Stellbrink C.

Med Klin (Munich). 2003 Feb 15;98(2):91-5. Review. German.

PMID:
12601533
16.

Once-daily enoxaparin in the outpatient setting versus unfractionated heparin in hospital for the treatment of symptomatic deep-vein thrombosis.

Chong BH, Brighton TA, Baker RI, Thurlow P, Lee CH; ASTH DVT Study Group..

J Thromb Thrombolysis. 2005 Jun;19(3):173-81.

PMID:
16082604
17.

Cardioversion under the guidance of transesophageal echochardiograhy in persistent atrial fibrillation: results with low molecular weight heparin.

Akdeniz B, Türker S, Oztürk V, Badak O, Okan T, Aslan O, Kozan O, Kirimli O, Aytekin D, Bariş N, Güneri S.

Int J Cardiol. 2005 Jan;98(1):49-55.

PMID:
15676166
18.

Transesophageal echocardiography-guided cardioversion of atrial fibrillation. Selection of a low-risk group for immediate cardioversion.

Fonseca N, Caetano F, Santos J, Seixo F, Bernardino L, Silvestre I, Cardoso P, Segurado F, Inês L.

Rev Port Cardiol. 2004 Mar;23(3):365-75. English, Portuguese.

PMID:
15185562
20.

Bleeding complications in patients with atrial fibrillation undergoing cardioversion randomized to transesophageal echocardiographically guided and conventional anticoagulation therapies.

Klein AL, Murray RD, Grimm RA, Li J, Apperson-Hansen C, Jasper SE, Goodman-Bizon AS, Lieber EA, Black IW; ACUTE Investigators..

Am J Cardiol. 2003 Jul 15;92(2):161-5.

PMID:
12860217

Supplemental Content

Support Center